Immix Biopharma, Inc.
IMMXNext catalyst
NXC-201 CAR-T
Light Chain (AL) Amyloidosis
Get an email about IMMX's next catalysts
Track Immix Biopharma (IMMX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 2 past
IMMX Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.18 | FQ end Sep/2026 | Call: tbd
NXC-201 CAR-T Phase 2 Est. Readout (NEXICART-2)
Estimated primary completion for NXC-201 CAR-T trial (NCT06097832) in Light Chain (AL) Amyloidosis. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NXC-201 CAR-T | Phase 2 | Light Chain (AL) Amyloidosis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Immix Biopharma, Inc.'s drug pipeline?β
CatalystAlert tracks 1 drug candidate in Immix Biopharma, Inc.'s (IMMX) pipeline across Phase 2. Its lead program is NXC-201 CAR-T (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Immix Biopharma, Inc.'s next FDA catalyst?β
Immix Biopharma, Inc.'s (IMMX) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IMMX biotech catalysts?β
Add IMMX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Immix Biopharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
